Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future
诺和诺德的“战略困局”：被过去所束缚，或将让它丧失未来

It’s possible to imagine a world in which Novo Nordisk remained a medium-to-large European pharma company, a little like Merck KGaA or Boehringer Ingelheim, ticking over for hundreds of years, quietly changing patients’ lives without being part of a once-in-a-generation breakthrough.
不难想象这样的世界：诺和诺德始终只是欧洲一家中大型制药公司，有点像默克集团或勃林格殷格翰，数百年来稳步运转，默默改善患者生活，却并未参与一次代际级的突破。